Supernus Pharmaceuticals | SUPN - Operating Profit


Supernus Pharmaceuticals reported $-21.04M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
Abbott USD 1.36B 775M Sep/2026
ANI Pharmaceuticals USD 51.84M 12M Sep/2026
Aurora Cannabis CAD -8.73M 1.3M Jun/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Canopy Growth CAD -17.58M 9.9M Jun/2026
Cara Therapeutics USD -7.05M 1.11M Mar/2026
Corcept Therapeutics USD 114.72M 73.42M Sep/2026
Eisai JPY 16.7B 8.03B Sep/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Novo Nordisk DKK 33.76B 25.86B Jun/2026
Pacira USD 2.57B 2.56B Sep/2026
Perrigo USD 27.2M 3.7M Sep/2026
Pfizer USD 662M 5M Sep/2026
Supernus Pharmaceuticals USD -21.04M 14.21M Jun/2026
United Therapeutics USD 241.3M 89.5M Sep/2026
Xeris Pharmaceuticals USD 5.17M 2.74M Jun/2026